- Home
- RLTY vs RPID Comparison
RLTY vs RPID Comparison
Compare RLTY & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLTY | RPID |
|---|---|---|
| Founded | 2022 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.8M | 204.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RLTY | RPID |
|---|---|---|
| Price | $14.53 | $2.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 50.9K | ★ 213.6K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 9.35% | N/A |
| EPS Growth | N/A | ★ 2.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,587,000.00 |
| Revenue This Year | N/A | $21.86 |
| Revenue Next Year | N/A | $26.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.74 |
| 52 Week Low | $12.90 | $1.86 |
| 52 Week High | $15.97 | $4.94 |
Technical Indicators
Market Signals| Indicator | RLTY | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 31.88 | 28.08 |
| Support Level | $14.45 | N/A |
| Resistance Level | $15.30 | $3.74 |
| Average True Range (ATR) | 0.24 | 0.30 |
| MACD | -0.13 | -0.19 |
| Stochastic Oscillator | 10.29 | 2.69 |
Price Performance
Historical ComparisonAbout RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.